CBAY Overview
Upcoming Projects (CBAY)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (CBAY)
-
2 Week Delay: Survey on Primary Biliary Cholangitis (PBC) and CymaBay Therapeutics’ Seladelpar
Tickers: CBAY, ICPT, GNFT, CVX
Executed On: Jan 10, 2024 at 06:12 PM EST -
Discussing the post-hoc analysis of the Phase 3 ENHANCE study of CymaBay's seladelpar for the treatment of primary biliary cholangitis (PBC)
Ticker: CBAY
Executed On: Aug 02, 2023 at 04:00 PM EDT -
Discussing the potential of CymaBay's seladelpar, a peroxisome proliferator-activated receptor, in development for primary biliary cholangitis
Ticker: CBAY
Executed On: Feb 06, 2023 at 11:00 AM EST
Upcoming & Overdue Catalysts (CBAY)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (CBAY)
-
CymaBay(CBAY) Halts Clinical Development of Seladelpar
Ticker: CBAY
Occurred on: Nov 25, 2019 -
CymaBay's(CBAY) Seladelpar in Primary biliary cholangitis (PBC) Data from completed Phase 2 trial to be presented at DDW May 20, 2019
Ticker: CBAY
Occurred on: May 20, 2019 -
Advancement to Phase 3 Studies of Arhalofenate Dependent on Securing Commercial Partnership
Ticker: CBAY
Occurred on: Mar 29, 2016 -
CymaBay (CBAY) to Present Two Phase 2 Studies of Arhalofenate for Gout Patients at the American College of Rheumatology Annual Meeting
Tickers: CBAY, CELG, AZN, REGN
Occurred on: Nov 07, 2015
Strategic Initiatives (CBAY)
-
CymaBay In Ongoing Discussions With Potential Partners For The Phase 3 Development of Arhalofenate
Ticker: CBAY
Announcement Date: Mar 29, 2016
